Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ... validation from Intuitive Surgical, the manufacturer of ... Triton-36 Instrument Cleaning System. This approval reflects the ... in cleanliness currently in place for the sterile ... validation for reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... R.I. , March 6, 2015 Troyen ... Medical Officer of CVS Health (NYSE: CVS ... Health in Washington, D.C. today. ... critical role in addressing health care cost and quality ... After making CVS/pharmacy the first national pharmacy chain to ...
(Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2
... 2011 As the nation seeks to expand ... burdensome costs, researchers from Harvard University, Brigham and ... CVS ) reported that preventative health care may ... to expanded use of cost-effective generic medications for ...
... WOODCLIFF LAKE, N.J., July 6, 2011 Par Pharmaceutical Companies, ... will host a conference call and live webcast on Wednesday, ... for the second quarter 2011. The Company will release its ... Access to the live webcast can be made ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 2CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 3CVS Caremark, Harvard and Brigham and Women's Research Shows Generic Medications are Changing the Economics of Treating Chronically Ill Patients 4
(Date:3/6/2015)... 06, 2015 Ticket Down is a reputable ... at the Moda Center. After being away from ... is showing no signs of letting up on his “Garth ... and his wife, Trisha Yearwood, to venues around the United ... their critically acclaimed tour to the Moda Center in Portland, ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... Bakersfield, California (PRWEB) March 06, 2015 ... $5.7 million jury verdict on March 5, 2015 in ... County. According to court documents, a jury of 12 ... she suffered from being implanted with an Ethicon TVT ... of nine men and three women also awarded $5 ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Jvion, ... the release of a Clostridium Difficile (C Diff) ... The C Diff use case is the latest ... span hospital acquired infections, chronic conditions, and individual ... the C Diff solution flags at risk individuals ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... that absorbs blue light has been linked to sleep disorders in ... 1 issue of the journal Sleep . As this type ... insomnia. "The strong link between lens yellowing and age could ... said Line Kessel, M.D., Ph.D., the study,s lead author. In ...
... of the speech information rate of seven languages concludes ... which languages are spoken, but much less variation in ... "A cross-linguistic perspective on speech information rate," to be ... journal Language , is co-authored by Franois Pellegrino, ...
... HealthDay Reporter , WEDNESDAY, Aug. 31 (HealthDay ... records instead of paper files could greatly improve care ... "did better and improved faster" at various kinds of ... author Dr. Randall D. Cebul, a professor of medicine ...
... WEDNESDAY, Aug. 31 (HealthDay News) -- Some breast cancer patients ... can skip hormone therapy without increasing their risk of death, ... had tumors that were hormone-receptor positive, which means they require ... tumors is designed to starve the breast cancer cells by ...
... modified a toxic chemical produced by tiny marine microbes and ... Writing today in ACS Medicinal Chemistry Letters , UF ... of marine cyanobacteria and made it more specifically toxic ... of the compound to mice with a form of colon ...
... an easy way to improve your health: trust your neighbors. ... that increasing trust in neighbors is associated with better self-reported ... where one fits into the income distribution in their local ... self-rated health," said Eileen Bjornstrom, an assistant professor of sociology ...
Cached Medicine News:Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Language speed versus efficiency: Is faster better? 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 2Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 3Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 2Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 3Health News:Trust in your neighbors could benefit your health, MU study shows 2
... Rusch Snap-Light™ laryngoscope blades are designed with ... fiber optic bundle can be removed to ... to reach areas. Our unique snap-on mechanism ... bright focused blades are interchangeable with other ...
... high quality fiberoptic system designed to meet ... fiberoptic laryngoscopes. The green color coding identifies ... to interconnect with other green coded systems. ... bright and focused light. The Greenspec pivot ...
Rigid plastic. Single use. Non-Sterile. The disposable laryngoscope blade that fits on a standard handle. Made of extremely rigid plastic. Bright white light out-performs metal blades. Single patient...
... Laryngoscopes are a high quality fiberoptic system ... greater standardization to fiberoptic laryngoscopes. The green ... indicates it's ability to interconnect with other ... offers a cool, bright and focused light. ...
Medicine Products: